|
| 37879077 | Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. | Blood | 2024 |
| 37952982 | Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001. | Br J Haematol | 2024 |
| 38054837 | Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients. | Leuk Lymphoma | 2024 |
| 37946611 | Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. | Br J Haematol | 2024 |
| 36222579 | Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals. | Leuk Lymphoma | 2023 |
| 37635400 | Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. | Am J Hematol | 2023 |
| 37665752 | Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. | Am J Hematol | 2023 |
| 37854355 | The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia. | Ther Adv Hematol | 2023 |
| 37585491 | Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. | Clin Cancer Res | 2023 |
| 37515433 | Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. | Am J Hematol | 2023 |
| 37696819 | Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors. | Blood Cancer J | 2023 |
| 37841255 | Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. | Front Immunol | 2023 |
| 37735426 | Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. | Blood Cancer J | 2023 |
| 37690903 | Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37647601 | Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. | Blood Adv | 2023 |
| 37608562 | Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. | Br J Haematol | 2023 |
| 37730483 | Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37671649 | Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel. | Am J Hematol | 2023 |
| 35405739 | Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. | Blood Adv | 2023 |
| 35633516 | Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. | Am J Hematol | 2023 |
| 36951293 | Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. | Br J Haematol | 2023 |
| 36951163 | Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). | Haematologica | 2023 |
| 36951156 | Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial. | Haematologica | 2023 |
| 37422688 | A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. | J Hematol Oncol | 2023 |
| 37156478 | Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2023 |
| 37187499 | Neutropenic Enterocolitis: An Uncommon, but Fearsome Complication of Leukemia. | J Hematol | 2023 |
| 37187201 | Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. | Lancet Haematol | 2023 |
| 37386016 | A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. | Blood Cancer J | 2023 |
| 37183966 | Ultrasensitive NGS MRD assessment in Ph+â¿¿ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. | Am J Hematol | 2023 |
| 37345488 | Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia? | Haematologica | 2023 |
| 37046645 | Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. | Cancers (Basel) | 2023 |
| 37441846 | Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. | Blood | 2023 |
| 37104058 | Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. | Blood Adv | 2023 |
| 37139599 | Maintenance therapy in acute myeloid leukemia: advances and controversies. | Haematologica | 2023 |
| 37102976 | A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. | Blood Cancer Discov | 2023 |
| 37334870 | Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. | Am J Hematol | 2023 |
| 37131217 | Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. | J Hematol Oncol | 2023 |
| 37196217 | Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class Rearrangements. | JCO Precis Oncol | 2023 |
| 36884300 | Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. | Blood Adv | 2023 |
| 36655608 | Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial. | Am J Hematol | 2023 |
| 36448227 | A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. | Cancer | 2023 |
| 36882573 | Association between bariatric surgery and outcomes in chronic myeloid leukemia. | Cancer | 2023 |
| 36402146 | Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. | Lancet Haematol | 2023 |
| 36399715 | North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. | Blood | 2023 |
| 36877196 | Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. | Am J Hematol | 2023 |
| 36715486 | Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. | Cancer | 2023 |
| 36801700 | PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. | Leuk Res | 2023 |
| 36502492 | Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. | Am J Hematol | 2023 |
| 36600670 | Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. | Am J Hematol | 2023 |
| 36458426 | A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. | Cancer | 2023 |